Push/Pull

WHO 2017 BPPL Survey, ENABLE-2 Call, OHE summary of NHS pilot

Dear All, A key theme of all discussions on Pull incentives is that substantial rewards should go only to molecules with high medical value. We’re still learning to define the idea of high value and today’s newsletter brings together 3 threads that feed into this conversation:  First, we have the idea a priority pathogen list.

Read More »

PASTEUR: Sign a letter to make it happen this year!

Dear All, As all regular readers of this newsletter know, I think that creation of suitable Pull incentives by passage of the PASTEUR Act in the United States is THE key to building a vibrant pipeline of products to address the international problem of AMR. PASTEUR came very close to passage at the end of 2022 …

Read More »

Lives saved + ROI of PASTEUR-like pull in Canada, UK, EU, Japan!

Dear All (and with thanks to Kevin for co-authoring), Building on their excellent analysis of the value over 30 years (29 Nov 2022 newsletter) to the United States as well the value to the entire globe of a PASTEUR-style pull that creates 18 new qualifying antibiotics, Silverman and Towse have now released country-by-country analyses using the

Read More »

Reports calling for Pull: US GAO, Global AMR R&D Hub

Dear All, Two important reports for your awareness this afternoon. First, the Global AMR R&D hub have responded to a request from the G7 Finance and Health Ministers to provide an update to their 2022 progress report in advance of upcoming G7 meetings. As background, recall that the Finance Ministers in 2021 (during the UK G7

Read More »

€100m HERA Invest fund; Sign to support PASTEUR; Superb AMR movie!

Dear All,  Expanding the available Push funding, the EU’s HERA (Health Emergency Preparedness and Response Authority) has created HERA Invest by allocating €100m in support early and late phases of clinical trials. HERA Invest is open on a rolling application basis to EU-based SMEs developing medical countermeasures that address one of the following cross-border health threats: (i)

Read More »

AMR Hearing in Congress, WHO BPPL Survey, & Vivli AMR Data Challenge

Dear All, Three things today… First, there is a newly announced hearing by the House Energy and Commerce at 9AM on this Friday, 28 April entitled “Antimicrobial Resistance: Examining an Emerging Public Health Threat.” Go here for details including a link for a livestream of hearing. It’s exciting to see this coming up … hopefully, it

Read More »

AMR Hearing in Congress, PASTEUR re-introduced … and more!

Dear All, It’s been a busy 48 hours .. three (and a half) things for you! First up, you will find notes below my signature on today’s “Antimicrobial Resistance: Examining an Emerging Public Health Threat” hearing in the US House of Representatives. The recording of today’s hearing is now available on YouTube. It was a fabulous 2 hours

Read More »

MHLW plan to pilot Pull incentives in Japan: Further details

Dear All, As a follow up the 19 Aug 2023 newsletter on MHLW’s work on Pull incentives (and with thanks to Yann Ferrise of GARDP for pointing out this out), we have an update in the 7 Aug 2023 edition of Nikkan Yakugyo (https://nk.jiho.jp/article/183026). It’s in Japanese and so again I must apologize for my lack

Read More »

Outstanding discussions of Pull, the NHS Pilot, and Antibiotic value

Dear All, The BEAM Alliance, along with its partners (CARB-X, the Novo REPAIR Impact Fund, the IMI AMR Accelerator, and the European Biotechnology Magazine) converted their annual AMR conference into a virtual event held 24-26 Aug 2021. As usual, it was excellent! I know we’re all really, REALLY tired of virtual meetings but the 2h/day x 3 day themed format worked well:

Read More »
Scroll to Top